Health care stocks fall as lawmakers, patients push for changes to their business models

Health care stocks fall as lawmakers, patients push for changes to their business models


UnitedHealth Group signage is displayed on a monitor on the floor of the New York Stock Exchange.

Michael Nagle | Bloomberg | Getty Images

Shares of major health-care companies fell as much as 5% on Wednesday as investors feared pressure from lawmakers and patients could force changes to their business models.

The declining stocks include UnitedHealth Group, Cigna and CVS Health, which operate three of the nation’s largest private health insurers and drug supply chain middlemen called pharmacy benefit managers, or PBMs. They also own pharmacy businesses. Shares of all three companies were down at least 4.8% in early afternoon trading.

The stock reaction on Wednesday appeared to be in response to new bipartisan legislation that aims to break up PBMs, which was first reported by the Wall Street Journal. PBMs have faced years-long scrutiny from Congress and the Federal Trade Commission over allegations they inflate drug costs for patients to boost their profits. 

The share moves also come as insurance companies and their practices face heightened public criticism following the fatal shooting of Brian Thompson, the CEO of UnitedHealth Group’s insurance arm, last week. Health stocks had already fallen in the days after Thompson’s killing.

A Senate bill, sponsored by Sens. Elizabeth Warren,  D-Mass., and Josh Hawley, R-Mo., would force the companies that own health insurers or PBMs to divest their pharmacy businesses within three years, the Journal reported. The lawmakers told the Journal that a companion bill is scheduled to be introduced in the House on Wednesday.

“PBMs have manipulated the market to enrich themselves—hiking up drug costs, cheating employers, and driving small pharmacies out of business,” Warren said in a release. “My new bipartisan bill will untangle these conflicts of interest by reining in these middlemen.”

The release added that healthcare companies that own both PBMs and pharmacies are a “gross conflict of interest that enables these companies to enrich themselves at the expense of patients and independent pharmacies.”

The largest PBMs – UnitedHealth Group’s Optum Rx, CVS Health’s Caremark and Cigna’s Express Scripts – are all owned by or connected to health insurers. They collectively administer about 80% of the nation’s prescriptions, according to the FTC.

PBMs sit at the center of the drug supply chain in the U.S., negotiating rebates with drug manufacturers on behalf of insurers, large employers and federal health plans. They also create lists of medications, or formularies, that are covered by insurance and reimburse pharmacies for prescriptions.

The FTC has been investigating PBMs since 2022. 

— CNBC’s Bertha Coombs contributed to this report



Source

Abortion pill makers brace for restrictions a year after Trump’s election
Health

Abortion pill makers brace for restrictions a year after Trump’s election

Mifepristone and Misoprostol pills are pictured Wednesday, Oct. 3, 2018, in Skokie, Illinois. Erin Hooley | Chicago Tribune | Tribune News Service | Getty Images Just over a year since Donald Trump was elected president again, the $6.9 billion abortion pill industry is operating under the same federal rules he inherited from former President Joe […]

Read More
Republicans push Obamacare tax credit alternatives as enrollment deadline looms
Health

Republicans push Obamacare tax credit alternatives as enrollment deadline looms

An Obamacare sign is displayed outside an insurance agency on Nov. 12, 2025 in Miami, Florida. Joe Raedle | Getty Images With enhanced Obamacare tax credits set to expire at the end of the year, Republicans are proposing new alternatives aimed at lowering the cost of health care. Their window for doing so is rapidly […]

Read More
Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target
Health

Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target

The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg | Getty Images Shares of Novo Nordisk on Monday fell as much 11% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal. The trial tested whether semaglutide — the […]

Read More